PhaseBio Pharmaceuticals, Inc. (PHAS) has an overall financial health rating of B with a composite score of 0 out of 5.
This suggests the company faces some financial challenges worth monitoring. Rating as of 2023-01-03.
| Date | Rating | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2023-01-03 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2022-12-30 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2022-12-29 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2022-12-28 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2022-12-27 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2022-12-23 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2022-12-22 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2022-12-21 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2022-12-20 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2022-12-19 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2022-12-16 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2022-12-15 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 |
